Market capitalization | $751.73m |
Enterprise Value | $1.14b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 40.95 |
EV/Sales (TTM) EV/Sales | 2.06 |
P/S ratio (TTM) P/S ratio | 1.35 |
P/B ratio (TTM) P/B ratio | 5.05 |
Revenue growth (TTM) Revenue growth | 10.40% |
Revenue (TTM) Revenue | $555.06m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:
3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 555 555 |
10%
10%
|
|
Gross Profit | 364 364 |
21%
21%
|
|
EBITDA | 75 75 |
3%
3%
|
EBIT (Operating Income) EBIT | 25 25 |
679%
679%
|
Net Profit | -39 -39 |
78%
78%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.
Head office | United States |
CEO | Robert Claypoole |
Employees | 970 |
Founded | 2011 |
Website | www.bioventus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.